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Background: It is well known that the quality of life of patients with chronic kidney disease can be improved by
dialysis. While previous studies have used retrospective designs and adhered to a standard target prescribed by
clinical guidelines, our study prospectively investigates the association between the adequacy of peritoneal dialysis
(PD) and measures of nutritional status on quality-of-life domains in a cohort of incident PD patients.
Methods: It was a prospective 6-month observational study. Eighty incident PD participants who were treated in a
hospital-based PD center were enrolled. The period of enrollment was January 2009–June 2010; follow-up
continued until December 2010. PD adequacy indices, including Kt/V urea, weekly Ccr (WCcr), measures of
nutritional status (albumin, BMI), and nPCR were measured at 1 month and 6 months after PD initiation. SF-36
health survey questionnaires were used to measure the quality of life. The outcomes were used to measure the
changes in the domains of the SF-36 after 6 months of PD therapy.
Results: Seventy-seven incident patients who underwent PD for 6 months were included in the study. The mean
age was 47.3 years, and the male-to-female ratio was 38:39. A peritoneal Kt/V urea value of 1.2, which was also the
baseline cutoff value, was found to have the highest influence on SF-36 domains. Patients with baseline peritoneal
Kt/V urea value of <1.2 showed improvement in the physical functioning and role limitation of physical functioning
components after 6 months of PD. In contrast, patients with baseline peritoneal Kt/V urea values of ≥1.2 showed
remarkable improvement in the general health, physical functioning, role limitation caused by physical problems,
and bodily pain components. However, the trend of improvement decreased in patients with baseline nPCR of
<1.2. Baseline renal WCcr did not influence the improvement in the SF-36 domains.
Limitations: A small cohort and a short observation period.
Conclusions: The baseline level of peritoneal Kt/V urea affected the components of the quality of life after PD
initiation. In contrast, a lower baseline nPCR level was associated with deterioration in the quality of life after PD
therapy.
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The concept of health-related quality of life (HRQoL) in
patients with chronic kidney disease (CKD), including
end-stage renal disease (ESRD), has evolved since the in-
ception of renal replacement therapy, evolving from en-
suring easy survival to achieving a sense of well-being
[1]. Patients with CKD tend to show a reduction in their
quality of life (QoL) because of the restrictions resulting
from CKD treatment. Multiple factors, such as the pres-
ence of co-morbidities, can further reduce the QoL.
Interventions aiming to improve the clinical condition
and the QoL of these patients are of paramount import-
ance, since the latter is directly associated with mortality.
The association between the reduction of QoL and pre-
ventable and controllable factors including diabetes [2],
old age [3], inadequacy of dialysis, inflammation and
poor nutrition, is still unclear. In addition, studies have
shown that dialysis initiation improves the QoL in ESRD
patients [4-8]. However, the association between dialysis
adequacy indices or nutritional parameters and QoL is
inconsistent. These results may be inconsistent owing to
the small sample of patients in those studies, non-ESRD-
specific assessments, inadequate observation periods, or
other factors.
Several validated, disease-specific HRQoL question-
naires can be used for the dialysis cohort, such as the
World Health Organization Quality of Life Survey
(WHOQOL), Short Form (SF)-36 health survey, the Kid-
ney Disease Quality of Life (kDQOL), and the Choices
Health Experiences Questionnaire (CHEQ). Patients with
Kt/V urea values above 2.0 undergoing peritoneal dialysis
(PD) were found to have higher total SF-36 scores than
patients with Kt/V urea values below 2.0 [6], although
some researchers argue that the correlation between Kt/
V urea values and SF-36 scores is not significant [8].
There are only 2 validated native-language editions of
questionnaires in Taiwan: the WHOQOL and the SF-36.
In Taiwan, the SF-36 questionnaires have been used as a
validation tool in a multi-center study comparing the
QoL between PD and hemodialysis patients [9].
In this study, we used the SF-36 to assess the QoL in
an incident cohort of PD patients. The purpose of the
study was to investigate which components of the SF-36
could be improved after PD initiation. In addition, the
influences of PD adequacy indices and nutritional status
measures on the components of the SF-36 were
explored.
Methods
Incident ESRD patients who consulted a PD institution
at a medical center in southern Taiwan between January
2009 and June 2010 were enrolled in this prospective
study. The following were the inclusion criteria: (1) new
PD patients; (2) aged above 17 years; (3) able to expressthemselves; (4) no history of psychiatric disease; and (5)
clinically stable with no evidence of chronic or acute
infections, inflammatory disorders, malignancy, or anti-
inflammatory drug use 3 months prior to enrollment.
The exclusion criteria were as follows: (1) aged below 17
years; (2) unable to receive PD therapy for three months
after PD initiation; (3) unable to complete the question-
naires by themselves; (4) major clinical events requiring
hospital admission; and (5) discontinuation of PD owing
to kidney transplantation, technique failure, death, trans-
fer to hemodialysis, or loss to follow-up. As per the study
protocol requirement, all patients had completed at least
6 months of consecutive PD therapy, and 77 of 80 clinic-
ally stable patients (38 men and 39 women) were finally
eligible. The mean age was 47.3 years. All the patients
were dialyzed using commercially available dialysate (pH
5.2; Dianeal PD solution; Baxter, Singapore) containing
40 mmol/L lactate. Forty-five patients received continu-
ous ambulatory PD (CAPD) therapy, with 4 exchanges
every day. Thirty-two patients received automated PD
(APD) therapy.
The QoL was measured using the Chinese version of
the Short Form (SF)-36 health survey questionnaire (Tai-
wan Standard Version 1.0)—a generic self-report QoL
instrument—comprising 36 items, which are assigned to
the following 8 domains: general health, physical func-
tioning, role limitation due to physical problems, bodily
pain, mental health, social functioning, role limitation
due to emotional problems, and vitality. The first 4
domains constitute the physical component scale, and
the next 4 constitute the mental component scale.
Higher scores indicate better QoL.
All the patients were asked to complete the SF-36
questionnaire prior to PD therapy as well as 6 months
after PD initiation. A standard peritoneal equilibrium
test (PET) was performed in the first month and then
after 6 months after PD initiation. The clinical character-
istics of all patients, including demographic and bio-
chemical data, PD adequacy indices of renal and
peritoneal Kt/V urea and creatinine clearance (Ccr), and
nutritional indices (serum albumin, normalized protein
catabolic rate [nPCR]) were collected as baseline infor-
mation at the beginning of the study. These data were
collected again at 6 months for statistical analysis.
The protocol for the study was approved by the Com-
mittee on Human Research at Kaohsiung Chang Gung
Memorial Hospital (CMRPG880091) and conducted in
accordance with the Declaration of Helsinki. All partici-
pants signed an informed consent form before taking
part in the study.
Statistical analysis
Using a general linear model, we determined an applic-
able Kt/V value to determine the effect of Kt/V on the
Table 2 Baseline patient characteristics and SF-36
domains stratified by peritoneal Kt/V urea levels
Peritoneal Kt/V urea
<1.2 (n = 11) ≧1.2 (n = 66)
Median (Range) Median (Range) P
Age (years) 54.3 (19.9 - 68.1) 48.8 (17.6 - 80.1) 1
Gender, Male (n) 5 33 0.780*
DM, n (%) 2 (18.2) 20 (30.3) 0.392a




Hb (g/dL) 8.9 (3 - 13) 8.9 (6 - 12) 0.708
Albumin (g/dL) 3.6 (2.3 - 4.2) 3.6 (2.4 - 4.9) 0.86
GPT (U/L) 12 (4 - 41) 15 (3 - 458) 0.676
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by us, the following patient characteristics were
recorded, grouped, and compared using the Mann–
Whitney test, Chi-square test, or likelihood ratio test:
age; gender; clinical data including values for peritoneal
urea Kt/V, residual renal urea Kt/V, total Kt/V, weekly
peritoneal Ccr, weekly residual renal Ccr, total weekly
Ccr, high-sensitivity C-reactive protein (hs-CRP), albu-
min, GPT, hemoglobin (Hb), and nPCR; and the 8 multi-
item domains of the SF-36. Thus, age, peritoneal Kt/V,
residual renal WCcr, and nPCR were regarded as inde-
pendent variables for exploring the effect of PD therapy
on SF-36 scores. Statistical analyses were performed
using the IBM SPSS Statistics 19 (SPSS Inc. Chicago, IL)
program.Cr (mg/dL) 12.4 (5.1 - 21.7) 12 (3.9 - 20.3) 1
hs-CRP (mg/L) 3.79 (0.2 - 40.1) 4.8 (0.2 - 199) 0.067
Peritoneal Kt/V urea 1.01 (0.7 - 1.2) 1.44 (1.2 - 2.3) <0.001
Residual renal Kt/V urea 0.79 (0.2 - 4.1) 0.54 (0 - 2.1) 0.111
Total Kt/V urea 1.78 (1.1 - 4.8) 2.11 (1.2 - 3.3) 0.003
Peritoneal WCcr L/week/
1.73m2
31.5 (10.9 - 40.2) 37.1 (20.5 - 55.2) <0.001
Residual renal WCcr
L/week/1.73m2
38.6 (8.8 - 262.4) 29.8 (0 - 204.8) 0.103
Total WCcr
L/week/1.73m2
68.2 (44.9 - 348.4) 72.7 (31.4 - 226.7) 0.58Results
Association between the baseline peritoneal kt/V urea
values and the scores of the SF-36 components
More components of the SF-36 were influenced by peri-
toneal Kt/V values when the cutoff peritoneal Kt/V value
was set at 1.2. General health, physical functioning, role
limitation due to physical problems, and bodily pain
scores had significantly improved when the peritoneal
Kt/V value was above 1.2. In contrast, the scores for only
the general health component improved when the peri-
toneal Kt/V value was below 1.2 (Table 1).nPCR 0.96 (0.5 - 1.5) 1.07 (0.5 - 1.6) 0.067
Physical functioning 76.7 (43.3 - 100) 76.7 (33.3 - 100) 0.727
Role limitation - physical 65.4 (46.2 - 100) 61.5 (38.5 - 100) 0.931
Bodily pain 63.6 (27.3 - 100) 72.7 (27.3 - 100) 0.172
General health 35 (30 - 90) 40 (20 - 100) 0.148
Vitality 31.5 (11.1 - 46.3) 35.2 (7.4 - 53.7) 0.676
Social functioning 50 (20 - 100) 60 (20 - 100) 0.537
Role limitation -
emotional
63.6 (54.5 - 100) 72.7 (36.4 - 100) 0.382
Mental health 27.5 (20 - 45) 30 (5 - 50) 0.811
* chi-square test, a likelihood ratio test.Stratification of the patients on the basis of peritoneal
kt/V urea and nPCR values
The patients were stratified into 2 groups on the basis of
baseline Kt/V urea values above or below 1.2. The periton-
eal Kt/V urea, total Kt/V urea, and weekly peritoneal Ccr
values (Table 2) were significantly different between both
groups. When the patients were stratified according to an
nPCR value above or below 1.2, those with nPCR values of
≥1.2 had higher total Kt/V urea and WCcr values than













β P-value β P-value β P-value β P-value β P-value β P-value β P-value β P-value
Peritoneal
Kt/V urea
<1.2 18.4 0.074 13.59 0.224 21.4 0.078 31.75 0.039 4.51 0.407 -3.65 0.814 3.51 0.754 4.97 0.440
1.2≦Kt/V<1.3 27.62 0.015 27.27 0.027 5.46 0.676 37.49 0.025 8.10 0.174 6.47 0.702 14.95 0.224 11.18 0.113
1.3≦Kt/V<1.4 24.92 0.016 27.39 0.016 22.7 0.061 37.47 0.015 5.94 0.274 7.84 0.612 17.80 0.115 7.64 0.235
1.4≦Kt/V<1.5 20.71 0.047 24.73 0.030 25.04 0.042 27.91 0.070 9.94 0.073 11.77 0.452 10.81 0.341 10.64 0.104
1.5≦Kt/V<1.6 4.98 0.678 14.64 0.266 25.51 0.075 12.28 0.491 -1.53 0.811 -14.57 0.426 0.70 0.957 4.14 0.585
≧1.6 20.91 0.028 18.96 0.067 19.83 0.076 43.74 0.002 10.59 0.037 6.66 0.641 12.33 0.235 7.55 0.204
Statistical method: general linear model.
Table 3 Baseline patient characteristics and SF-36
domains stratified by nPCR levels
nPCR
<1.2 (n = 55) ≧1.2 (n = 22)
Median (Range) Median (Range) P
Age (years) 50.7 (17.6 - 80.1) 47.5 (19.9 - 68.1) 0.665
Gender, Male (n) 5 33 0.780*
DM, n (%) 2 (18.2) 20 (30.3) 0.392a





Hb (g/dL) 9 (3 - 13) 8.8 (6 - 11) 0.388
Albumin (g/dL) 3.6 (2.4 - 69) 3.5 (2.3 - 4.7) 0.663
GPT (U/L) 15 (3 - 458) 13.5 (7 - 39) 0.885
Cr (mg/dL) 11.5 (5.4 - 21.7) 12.6 (3.9 - 20.1) 0.564
hs-CRP (mg/L) 3.33 (0.2 - 199) 7.86 (0.5 - 65.2) 0.299
Peritoneal Kt/V urea 1.36 (0.7 - 2.3) 1.43 (0.7 - 2.2) 0.051
Residual renal Kt/V urea 0.54 (0 - 1.44) 0.91 (0 - 4.1) 0.009
Total Kt/V urea 1.92 (1.1 - 3.0) 2.34 (1.8 - 4.8) <0.001
Peritoneal WCcr L/week/
1.73m2
35.3 (20.9 - 55.2) 36 (10.9 - 52.1) 0.973
Residual renal WCcr L/
week/1.73m2
29 (0 - 204.8) 39.2 (0 - 262.4) 0.167
Total WCcr L/week/1.73m2 68.8 (31.4 - 226.7) 84.4 (45.6 - 348.4) 0.007
nPCR 0.96 (0.5 - 1.2) 1.35 (1.2 - 1.6) <0.001
Physical functioning 76.7 (33.3 - 100) 78.3 (36.7 - 100) 0.612
Role limitation - physical 61.5 (38.5 - 100) 65.4 (46.2 - 100) 0.769
Bodily pain 72.7 (27.3 - 100) 72.7 (27.3 - 100) 0.659
General health 40 (20 - 100) 35 (20 - 90) 0.416
Vitality 35.2 (7.4 - 51.9) 34.3 (11.1 - 44.4) 1
Social functioning 60 (20 - 100) 60 (20 - 80) 0.257
Role limitation - emotional 68.2 (36.4 - 100) 68.2 (45.5 - 100) 1
Mental health 30 (10 - 50) 30 (5 - 45) 0.938
* chi-square test, a likelihood ratio test.
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the groups stratified on the basis of cutoff values of 1.2 of
Kt/V urea or nPCR values (Tables 2 and 3).
The effects of baseline peritoneal kt/V urea, renal WCcr,
and nPCR values on the scores of the SF-36 components
after 6 months of PD
The patients who had baseline peritoneal Kt/V urea
values of <1.2 showed an improvement in physical func-
tioning and role limitations due to physical problems
after 6 months of PD therapy. Patients who had baseline
peritoneal Kt/V urea of ≥1.2 showed improvement in
general health, physical functioning, role limitation due
to physical problems, and bodily pain (Table 4). Residualrenal function of either <40 Lweek-11.73 m-2 or ≥40
Lweek-11.73 m-2 did not have an impact on SF-36
scores after 6 months of PD therapy. Deterioration was
observed in all the components of the SF-36 after 6
months of PD therapy in patients with baseline nPCR
values of <1.2 (Table 4).
Discussion
Small solute clearance measured by Kt/V urea is known
to be one of the major determinants of dialysis adequacy.
A growing body of evidence has suggested that a strong
link exists between Kt/V urea values and mortality rates
in dialysis populations [10]. Therefore, to reduce the risk
of mortality and improve dialysis adequacy, the total
(renal + peritoneal) Kt/V urea value should not be less
than 1.7 for small solute removal, according to the guide-
lines of the Kidney Disease Outcomes Quality Initiative
(KDOQI) and the International Society for Peritoneal
Dialysis (ISPD) [11,12]. To reach this target, however,
patients might experience adverse effects, including her-
nias (from the increased intra-abdominal pressure due to
large volumes of dialysis solution), weight gain, and other
metabolic consequences due to increased exposure to
glucose. Furthermore, the increased amount of time
needed to perform the exchanges is less acceptable to
patients. These factors might not only adversely affect
the willingness of the patients to continue PD therapy
but also affect the QoL in incident PD patients. However,
one study reported that a lower Kt/V urea target was
associated with a similar survival rate [13], leading us to
consider what the impact of a lower Kt/V urea target
would be on QoL. In our study, we carefully stratified
our patients on the basis of peritoneal Kt/V urea values
into 2 groups. Peritoneal Kt/V urea is the major compo-
nent of total weekly Kt/V urea and is the critical compo-
nent targeted in dialysis regimens. We found that
patients with a peritoneal Kt/V urea value of >1.2
experienced significant improvement in the QoL, espe-
cially in the domains of general health, physical function,
and role limitation due to physical problems, at 6
months after the initiation of PD. Our results suggest
that PD on its own is highly beneficial in improving the
QoL in patients whose peritoneal Kt/V urea value is
above 1.2. This result implies that some domains of the
QoL could be improved after 6 months of PD therapy
with a lower peritoneal Kt/V urea target. However, the
influence of a lower peritoneal Kt/V urea value on long-
term QoL and patient survival needs to be further inves-
tigated. Our study also suggests that it might not be ne-
cessary to pursue a higher adequacy target at the
expense of QoL in the early phase of PD initiation. By
not pursuing a higher adequacy target, the early discon-
tinuation of incident PD patients observed occasionally
can be avoided.
Table 4 Multivariate analysis using the general linear model to assess the difference of influence on the SF-36 between
one month and six months following peritoneal dialysis therapy
Physical functioning Role limitation –physical Bodily pain General health
β (CI) P β (CI) P β (CI) p β (CI) p
Age -0.309 (-0.67-0.05) 0.09 -0.357 (-0.75-0.03) 0.07 -0.24 (-0.66-0.18) 0.262 -0.266 (-0.79-0.26) 0.32
Peritoneal Kt/V
<1.2 26.971 (3.81-50.14) 0.023 34.326 (9.21-59.44) 0.008 25.518 (-1.88-52.91) 0.067 30.703 (-3.53-64.94) 0.078
≧1.2 21.166 (1.64-40.70) 0.034 26.026 (4.85-47.20) 0.017 23.245 (-0.15-46.34) 0.049 33.373 (4.51-62.24) 0.024
Residual renal WCcr
<40 2.824 (-7.24-12.89) 0.578 -4.666 (-15.58-6.25) 0.397 -3.383 (-15.29-8.52) 0.573 10.481 (-4.40-25.36) 0.164
≧40 0 – 0 – 0 – 0 –
nPCR
<1.2 -5.645 (-16.25-4.96) 0.292 -3.325 (-14.82-8.17) 0.566 -0.083 (-12.62-12.46) 0.99 -9.164 (-24.83-6.51) 0.247
≧1.2 0 – 0 – 0 – 0 –
Vitality Social functioning Role limitation- emotional Mental health
β (CI) p β (CI) P β (CI) P β (CI) p
Age -0.089 (-0.28-0.10) 0.346 0.107 (-0.42-0.63) 0.687 -0.154 (-0.55-0.24) 0.437 -0.142 (-0.37-0.08) 0.206
Peritoneal Kt/V
<1.2 11.974 (-0.21-24.16) 0.054 6.724 (-27.39-40.83) 0.695 19.574 (-5.92-45.07) 0.13 11.234 (-3.18-25.65) 0.125
≧1.2 9.276 (-1.0-19.55) 0.076 2.663 (-26.09-31.42) 0.854 15.297 (-6.20-36.79) 0.16 8.402 (-3.75-20.55) 0.172
Residual renal WCcr
<40 2.936 (-2.36-8.23) 0.273 13.906 (-0.92-28.73) 0.066 -0.775 (-11.86-10.31) 0.889 0.949 (-5.32-7.21) 0.763
≧40 0 – 0 – 0 – 0 –
nPCR
<1.2 -6.484 (-12.06- -0.91) 0.023 -13.46 (-29.07-2.15) 0.09 -6.162 (-17.83-5.51) 0.296 -2.398 (-9.0-4.20) 0.471
≧1.2 0 – 0 – 0 – 0 –
Multivariate analysis:
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trogen appearance (PNA), can be used to assess dietary
protein intake in patients who are in a steady state. It
has also been adopted as a reference value to adjust dia-
lysis prescription. When poor nutrition (e.g., nPCR< 0.8
gkg-1day-1) or inadequate dialysis (e.g., Kt/V urea< 1.2)
is apparent, the dialysis prescription has to be adjusted
to meet the clinical situation. Moreover, to ascertain
whether a significant change has occurred may require sev-
eral months of nPCR and Kt/V urea level monitoring. A
previous study has demonstrated that mortality rates
increased in dialysis patients with nPCR values of less than
0.8 gkg-1day-1 or greater than 1.4 gkg-1day-1 [14]. Among
patients with nPCR levels between 0.8 gkg-1day-1 and 1.2
gkg-1day-1, an increase or decrease in protein intake during
the first 6 months was associated with an increase or de-
crease in the survival rate over the subsequent 18 months,
respectively. Thus, reduced survival is associated with an
initially low nPCR and decreased protein intake over time.
In the present study, patients with baseline nPCR values of
>1.2 gkg-1day-1 had higher renal Kt/V urea values andhigher weekly Ccr values than those with nPCR values of
<1.2 gkg-1day-1. Patients with nPCR values greater than
1.2 gkg-1day-1 showed improvement in SF-36 domain
scores after 6 months of PD therapy. In contrast, patients
with nPCR values of <1.2 gkg-1day-1 showed a decrease in
SF-36 domain scores after 6 months of PD therapy. The
exact mechanism by which residual renal function improves
the QoL in subjects with nPCR values of >1.2 gkg-1day-1
needs to be further investigated. However, this finding
implicates nutritional status as key factor in QoL improve-
ment with PD initiation. Therefore, it is essential to devise a
strategy to increase the nutritional status primarily in the
early phase of PD commencement.
In the past few years, some investigators have focused
on the reasons for the early discontinuation PD therapy
by patients. The NECOSAD study demonstrated that
the psychosocial effect of PD therapy was a one of the
major reasons why patients discontinued therapy in the
first 3 months [15]. Another study from a single PD
center also showed that psychosocial effects were a
major cause of early discontinuation of therapy in the
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has shown that the measures of social relationships and
physical health of PD patients did not significantly
change during the early and late phases of treatment
[17]. Furthermore, it has been found in one study that
emotional defensiveness affects the physical and mental
components of HRQoL in patients undergoing dialysis
[18]. In that study, the incident PD patients needed an
adjustment period to adapt to their uncertain psycho-
logical status; the complex, time-consuming PD ex-
change procedure affected their response to PD
therapy. This finding suggests that psychological effects
must not be ignored in the management of patients
undergoing dialysis. Our study clearly showed that PD
could improve the QoL, as measured by the SF-36 in-
strument, after 6 months of therapy. However, we
found that a lower peritoneal Kt/V urea value further
contributed to a remarkable improvement in the QoL.
We assume that a more satisfactory PD prescription
might reduce the psychosocial burden on incident PD
patients, even though it would attain a lower adequacy
index. This approach did not sacrifice the QoL in inci-
dent PD patients, as per our results.Conclusion
In summary, the QoL in incident PD patients can be
improved with a low of Kt/V urea value in the PD pre-
scription. Moreover, lower nPCR levels will offset the
benefits of PD initiation on the QoL improvement. Add-
itionally, a few aspects of the QoL domains in the SF-36
could be further improved in 6-month PD therapy in the
cohort with low Kt/V urea levels. The results could guide
medical staff in individualizing the medical plan for inci-
dent PD patients. We conclude that a stepwise PD pro-
gram is essential for incident PD patients. This gradual
approach to PD prescription need not be at the expense
of QoL in incident PD patients.Abbreviations
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